Quarterly ResultMay 14, 2026, 04:08 PM
Alpha Cognition Q1 Net Loss Widens to $6.48M; Product Revenue Soars
AI Summary
Alpha Cognition Inc. reported a significant increase in net loss to $6.48 million for Q1 2026, up from $1.73 million in Q1 2025, despite total revenue growing by 20.7% to $3.53 million. This was primarily driven by a 910% surge in product revenue following the launch of its ZUNVEYL oral tablet formulation, but operating expenses also rose sharply. The company also corrected an immaterial accounting error related to the classification of certain Canadian dollar denominated options.
Key Highlights
- Net loss widened to $6.48 million in Q1 2026 from $1.73 million in Q1 2025.
- Total revenue increased 20.7% to $3.53 million in Q1 2026 from $2.93 million.
- Product revenue surged 910% to $3.50 million in Q1 2026, driven by ZUNVEYL launch.
- Operating expenses increased 83.6% to $11.63 million in Q1 2026.
- Net cash used in operating activities rose to $11.80 million from $2.04 million.
- Cash and cash equivalents decreased to $54.25 million from $66.05 million since Dec 31, 2025.
- Granted 509,715 Restricted Stock Units (RSUs) with a fair value of $3.34 million.
- Corrected immaterial accounting error for CAD Options, restating Q1 2025 net loss.